ArticleEndocrinology, diabetes & metabolism2025
Plasma Fatty Acid Profiles Modulate PPARγ Expression in Adipose Tissue: A Lipidomic Insight Into Obesity-Related Metabolic Dysregulation.
Article in Endocrinology, diabetes & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma Fatty Acid Profiles Modulate PPARγ Expression in Adipose Tissue: A Lipidomic Insight Into Obesity-Related Metabolic Dysregulation.Endocrinology, diabetes & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to investigate the relationship between plasma fatty acids (FAs), FA-derived factors and PPARγ expression in visceral and subcutaneous adipose tissues (VAT and SAT) of obese and nonobese adults.
methodsThis cross-sectional study involved 167 adults aged 19 to 65. Samples of VAT and SAT were obtained during elective abdominal surgeries. Participants were divided into two groups: nonobese (BMI < 30 kg/m
resultsObese individuals had higher PPARγ gene expression in both VAT and SAT compared to nonobese participants (p < 0.001). Eighteen FFAs and three new FA-derived factors were identified in both groups, accounting for 69% of the variance in nonobese individuals and 71% in obese individuals. After adjusting for confounding factors, saturated FA (SFA) was associated with PPARγ expression in the SAT of the nonobese group (β = -0.12, p = 0.019). Additionally, total FAs (β = -0.02, p = 0.017), SFA (β = -0.06, p = 0.048), monounsaturated FA (MUFA) (β = -0.08, p = 0.020), polyunsaturated FA (PUFA) (β = -0.03, p = 0.039) and omega-6 FA (β = -0.03, p = 0.040) were associated with VAT PPARγ expression among obese individuals. Conversely, an inverse correlation was observed between factor I of FAs and SAT PPARγ expression in nonobese individuals (β = -0.15; p = 0.027).
conclusionThese findings suggest that alterations in plasma FA profiles are associated with PPARγ gene expression, particularly in obese individuals. This fact highlights the potential role of dietary FAs in metabolic regulation and health issues related to obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.